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Lung cancer is the worldwide leading cause of cancer-related mortality in men and 
second leading in women. Brain metastases (BM) account for 10% of non-small cell 
lung cancer (NSCLC) patients at initial presentation, with another 25–40% developing 
BM during the course of their disease. In the last decade, the field of precision oncology 
has led to the discovery of a multitude of heterogenous molecular abnormalities within 
NSCLC as well as the development of tyrosine kinase inhibitors that target them. In this 
review, the focus will be on targeted therapy and immunotherapy that show efficacy 
in BM rather than conventional treatment for multiple BM (such as surgical resection, 
WBRT, or stereotactic radiosurgery).
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inTRODUCTiOn
Lung cancer is the worldwide leading cause of cancer-related mortality in men and second leading in 
women (1). Brain metastases (BM) account for 10% of non-small cell lung cancer (NSCLC) patients 
at initial presentation (2), with another 25–40% developing BM during the course of their disease 
(3). The general metastatic NSCLC population survival is approximately 12 months, with a median 
progression-free survival (PFS) range from 3 to 6 months (4). BM are associated with poor prognosis, 
and the median survival ranges from 2.4 to 4.8 months for patients with BM who receive whole-brain 
radiation therapy (WBRT) (5). While the standard of care for BM remains radiotherapy, determining 
the optimal treatment between high-dose-focused radiations via stereotactic radiosurgery (SRS) 
alone versus WBRT remains controversial. A retrospective multi-institutional retrospective study 
showed a survival advantage in patients with fewer than four BM less than 4 cm in size (n = 189 for 
NSCLC) who were treated with SRS compared to those treated with WBRT [adjusted hazard ratio 
(HR) for NSCLC, 0.58; 95% confidence interval (CI), 0.38–0.87; P = 0.01] (6).
The treatment of BM is important in maintaining a good quality of life and limiting cognitive 
impairment and neurological dysfunction. In the last decade, the field of precision oncology has led 
to the discovery of a multitude of heterogenous molecular abnormalities within NSCLC as well as 
the development of tyrosine kinase inhibitors (TKIs) that target them (7).
Patients with untreated BM have been excluded from most clinical trials of systemic therapy 
for two reasons: (1) historically poor prognosis and (2) presumed poor blood–brain barrier (BBB) 
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penetration by experimental drugs. Thus, the efficacy of these 
drugs in controlling NSCLC-related BM remains controversial.
In this review, the focus will be on targeted therapy and immu-
notherapy that show efficacy in BM rather than conventional 
treatment for multiple BM (such as surgical resection, WBRT, or 
SRS), or some combination of the three.
AnAPLASTiC LYMPHOMA KinASe  
(ALK)-ReARRAnGeD nSCLC
The control and prevention of BM have emerged as an impor-
tant therapeutic issue as systemic therapies with TKIs continue 
to improve the duration of disease control for patients with 
oncogene-driven NSCLCs (8). BM have been reported in about 
24% of ALK-rearranged NSCLC patients at diagnosis, making 
intracranial activity an important feature of all ALK-targeted 
therapies (9).
Crizotinib
Crizotinib was the first ALK and ROS1 (c-ros oncogene 1) inhibi-
tor, approved for treatment of ALK-rearranged NSCLC. Crizotinib 
has shown evidence of potential clinical benefit in patients with 
a baseline of BM. PROFILE 1014, a phase 3 prospective study 
in ALK-positive NSCLC, demonstrated higher intracranial dis-
ease control rate (IDCR) with first-line crizotinib compared to 
chemotherapy in patients with treated BM. Although intracranial 
time to progression was improved, it was not significant (ITT 
population: HR, 0.60; 95% CI, 0.34–1.05; P = 0.069; treated BM 
present: HR, 0.45; 95% CI, 0.19–1.07; P = 0.063; BM absent: HR, 
0.69; 95% CI, 0.33–1.45; P = 0.323) (10). In patients with BM, the 
PFS was greatly improved with crizotinib versus chemotherapy 
(BM present: HR, 0.40; P < 0.001; median, 9.0 versus 4.0 months, 
respectively) and in the intent-to-treat population (HR, 0.45; 
P < 0.001; median, 10.9 versus 7.0 months, respectively). IDCR 
in patients with BM was significantly higher with crizotinib 
compared with chemotherapy (56 versus 25% at 24  weeks, 
respectively) (10) (Table 1).
Furthermore, a retrospective pooled analysis of single-arm 
phase 1 and 2 studies of crizotinib in advanced ALK-positive 
NSCLC, PROFILE 1007 (13) and 1005 (12), demonstrated a 
median overall survival (OS) of 29.6 months for 120 patients who 
were allowed to continue crizotinib beyond progressive disease 
(PD) because they continued to derive clinical benefit from it. 
Only 18% of previously untreated BM patients achieved an over-
all intracranial response rate (ICRR), with an IDCR of 56% (95% 
CI, 46–66%) at 12 weeks (11) (Table 1).
Inevitably, the brain is the most common site of PD after 
resistance to crizotinib because of inadequate central nerv-
ous system (CNS) penetration of the drug or the biological 
change in the tumor (28). Hence, progression of preexisting 
or development of new intracranial lesions in up to 70% of 
patients while receiving therapy was a common manifestation 
of acquired resistance to crizotinib (29). Most systemic cyto-
toxic chemotherapies and some TKIs seem to cross the intact 
BBB inefficiently (30).
Limited intracranial response of crizotinib might be related to 
lower concentrations of the drug in cerebrospinal fluid compared 
with the plasma concentration (0.616 versus 237 ng/mL, respec-
tively, 5 h after administration of a 250 mg dose) (31).
Ceritinib
Ceritinib is another ALK inhibitor approved for ALK-rearranged 
NSCLCs that have progressed on crizotinib.
In vitro studies have found that ceritinib has a 20-fold greater 
potency to inhibit ALK than crizotinib and a 12-fold greater 
potency than alectinib (32). Ceritinib was found to cross the intact 
BBB in rats with a brain-to-blood exposure ratio of approximately 
15%, although no human data exists (33).
In the phase 1 ASCEND-1 study, ceritinib demonstrated 
activity in ALK-rearranged locally advanced or metastatic cancer 
NSCLC patients, including both ALK-naïve and ALK-pretreated 
patients who had progressed following multiple lines of chemo-
therapy. Thirty one percent of the ALK inhibitor-naïve patients 
and 60% of ALK inhibitor-pretreated patients had BM, respec-
tively. There were 94 patients with retrospectively confirmed BM 
and at least one post-baseline imaging. IDCR was 79% (15 of 
19) in ALK inhibitor-naïve patients and 65% (49 of 75) in ALK 
inhibitor-pretreated patients (14). Overall ICRR was 34.5% (34) 
(Table 1).
In the ASCEND-2 phase 2 study, ceritinib showed a durable 
response in ALK-rearranged NSCLC patients who progressed 
on chemotherapy and crizotinib, including patients with BM. 
Moreover, 20 of the 100 patients with baseline BM had active 
target lesions at baseline. The investigator-assessed overall ICRR 
was 45% (95% CI, 23.1–68.5%), while the IDCR was 80% (n = 20, 
95% CI, 56.3–94.3) (15) (Table 1).
In the ASCEND-3 phase 2 study of ceritinib in ALK-inhibitor-
naïve NSCLC, 40.3% (50/124 patients) presented with BM at 
baseline. Fifty-four percent (27/50 patients) had received prior 
radiotherapy to BM. Updated data from ESMO 2016 showed an 
ICRR of 61.5% (8/13) in patients with measurable BM at baseline 
and an IDCR of 76.9% (10/13) (16) (Table 1).
Alectinib
Alectinib is another powerful ALK inhibitor that has shown 
activity in crizotinib-resistant patients. A phase 2 study in ALK-
positive NSCLC patients observed an objective response rate of 
48% (35).
A hurdle in treating BM is achieving a higher rate of drug 
concentration in the brain because of the BBB. In animal 
models, alectinib has a high brain-to-plasma ratio (0.63–0.94) 
and activity in intracranial tumor implantation models (36). 
Alectinib penetrates into the CNS (2.69  nmol/L) where it 
is able to exceed the in  vitro concentration for ALK inhibi-
tion (1.9  nmol/L) (35, 37). Alectinib human studies show a 
50% CNS distribution, but of a 12-fold lesser potency than 
ceritinib (33).
Unlike crizotinib and ceritinib, studies also suggest that alec-
tinib is not a substrate of P-glycoprotein (P-gp), a key drug efflux 
pump typically expressed in the BBB (36), thus allowing for a 
higher rate of drug penetration through the BBB.
Pooled data analysis of NP28761 and NP28673, two single-arm 
phase 2 trials, evaluated the CNS effect of alectinib in pretreated 
ALK-rearranged NSCLC patients (19). NP28761 was limited 
TABLe 1 | intracranial effect of tyrosine kinase inhibitors ALK inhibitors and epidermal growth factor receptor (eGFR) inhibitors in trials in non-small cell 
lung cancer (nSCLC).
Trial Treatment iDCR iCRR
ALK inhibitors
PROFILE 1014 (10) Crizotinib 56% at 24 weeks Not described
PEM + CBDCA or CDDP 25% at 24 weeks Not described
Pooled analysis of Ref. (11) Crizotinib 56% at 12 weeks (previously untreated) 18% (previously untreated)
PROFILE 1005 (12)
PROFILE 1007 (13)
ASCEND-1 (14) Ceritinib 65% (pretreated) 34.5%
79% (naïve)
ASCEND-2 (15) Ceritinib 80% 45%
ASCEND-3 (16) Ceritinib 76.9% 61.5%
NCT01449461 (17) Brigatinib 83% (measurable) 50%
85% (non-measurable) 31%
NP28673 (18) Alectinib 85.3% 58.8% (measurable)
84.5% (pretreated) 46.4% (non-measurable)
NP28673 and NP28761 (19) Alectinib 90.0% (measurable BM) 64.0% (measurable BM)
85.3% (measurable and/or  
non-measurable BM)




J-ALEX (20) Alectinib 92.9% 85.4%
ALTA (21) Brigatinib 88% (90 mg) 36% (90 mg)
83% (180 mg) 67% (180 mg)
NCT01970865 (22) Lorlatinib Not described 44% (targetable and non-targetable)
60% (targetable)
eGFR inhibitors
Pooled analysis of published data Erlotinib or gefitinib 75.7% 51.8%
Fan et al. (23)
Retrospective analysis Pulsatile high-dose weekly erlotinib Not described 67%
Grommes et al. (24)
LUX-Lung 3 and LUX-Lung 6 (25) Afatinib Not assessed Not assessed
BLOOM (26) Osimertinib Not described 76% (33% LM improvement and 
43% LM SD)
BLOOM (27) AZD3759 Not described 52.4% (measurable)
IDCR, intracranial disease control rate; ICRR, intracranial response rate; PEM, pemetrexed; CBDCA, carboplatin; CDDP, cisplatin; BM, brain metastases; RT, radiotherapy; LM, 
leptomeningeal metastases; SD, stable disease.
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to North America only (NCT01871805), while NP28673 was a 
global study (NCT01801111). One hundred thirty-six patients 
had baseline measurable BM (60% of the overall study popula-
tions). For patients with baseline measurable BM, the ICRR was 
64.0% (95% CI, 49.2–77.1%) with 11 (22%) complete responses 
(CR) in the brain, the IDCR was 90.0% (95% CI, 78.2–96.7%), 
and the duration of response (DOR) was 10.8 months (95% CI, 
7.6–14.1 months) (19) (Table 1). For patients with measurable 
and/or non-measurable baseline BM, the IDCR was 42.6% (95% 
CI, 34.2–51.4%), the IDCR was 85.3% (95% CI, 78.2–90.8%), and 
the median DOR was 11.1 months (95% CI, 10.3 months to not 
evaluable) (19). For patients with prior radiotherapy (n =  95), 
the ICRR was 35.8% (95% CI, 26.2–46.3%) and 58.5% (95% CI, 
42.1–73.7%) for patients without prior radiotherapy (n =  41) 
(Table 1).
Updated intracranial response data on the 61/138 patients with 
baseline BM the global phase 2 NP28673 study was presented at 
ESMO 2016. In the measurable BM group (n =  34), the ICRR 
was 58.8% (95% CI, 40.7–75.4), while IDCR was 85.3% (95% CI, 
68.9–95.1) and the median DOR was 11.1 months (Table 1). In 
the measurable and non-measurable group (n = 84), the ICRR 
was 46.4% (95% CI, 35.5–57.7), while IDCR was 84.5% (95% CI, 
78–91.5) and median DOR was 11.2 months (18) (Table 1).
More recently, J-ALEX, a phase 3 study comparing alectinib 
and crizotinib in treatment naive patients in Japan, showed an 
ORR of 85.4% in the alectinib group versus 70.2% in the crizo-
tinib group (20). In patients with BM, the HR for alectinib versus 
crizotinib was 0.08 (95% CI, 0.01–0.61). The J-ALEX trial enrolled 
14 patients with asymptomatic BM in the alectinib arm. Only one 
of the patients with BM treated with alectinib had progressed by 
the time of data cut-off (IDCR of 92.9%) (20) (Table 1). Thus, 
reducing CNS progression in patients with ALK-positive NSCLC 
with alectinib could be achievable if alectinib is used in the 
first-line setting.
4Wong Targeted Therapy/Immunotherapy in BM
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The Global ALEX trial is currently ongoing, also comparing 
alectinib versus crizotinib in first-line ALK-positive NSCLC but 
on a global scale. If the J-ALEX results are confirmed with this 
trial, alectinib could likely replace crizotinib as the standard first-
line therapy for ALK-positive NSCLC in the future, especially 
those with BM.
Brigatinib, Lorlatinib, and Others
Brigatinib is an ALK inhibitor with preclinical activity against 
rearranged ALK and clinically identified crizotinib-resistant 
mutants. NCT01449461, a phase 1/2 single-arm, open-label, 
multicenter study in patients with advanced malignancies is 
ongoing. In a post hoc independent radiological review of patients 
with baseline BM, 6/12 patients with lesions ≥10 mm had a brain 
response (≥30% decrease in sum of longest diameters of target 
lesions) and 8/26 patients with only non-measurable lesions had 
disappearance of all lesions. ICRR for brigatinib with measure-
able BM was 50% and the IDCR was 83% (17). In non-measurable 
BM, the ICRR was 31%, IDCR was 85%, median intracranial PFS 
was 97  weeks, and median duration of intracranial response 
82 weeks (Table 1). In ALTA, a phase 2 trial of brigatinib, ORR 
in arm A (90 mg qd) was 46% while ORR in arm B (90 mg qd 
for 7 days followed by 180 mg qd) was 54%. Seventy-one percent 
(arm A) and 67% (arm B) had BM (21) (Table 1).
Since CNS progression is a common site of relapse in NSCLC 
ALK/ROS1 mutation patients, lorlatinib was developed as a selec-
tive brain-penetrant ALK/ROS1 TKI active against most known 
resistance mutations. The phase 1 portion of the ongoing phase 
1/2 study NCT01970865 enrolled patients with ALK+ or ROS1+ 
NSCLC with or without BM and were treatment naïve or had 
disease progression after ≥1 TKIs. Preliminary results revealed 
an objective ICRR of 44% in targetable and non-targetable lesions 
and 60% in targetable lesion, respectively (22) (Table 1).
Additional second-generation ALK inhibitors shown 
to have efficacy in the brain include ASP3026, X396, and 
entrectinib (38).
ePiDeRMAL GROwTH FACTOR 
ReCePTOR (EGFR) TKis
First-Generation TKis
Approximately 33% of patients with NSCLC harboring tumors 
with EGFR-TKI-sensitizing mutations develop BM during 
treatment (39). Evidence suggests that EGFR TKIs have some 
limited BBB penetration (40, 41). In a pooled analysis including 
464 patients from 16 trials to study the efficacy of EGFR TKIs 
in NSCLC patients with activating EGFR mutations with BM 
showed that EGFR TKIs produce significant beneficial effects, 
with a pooled objective ICRR of 51.8%, IDCR of 75.7%, median 
PFS of 7.4 months, and OS of 11.9 months (23) (Table 1).
Although erlotinib is effective for EGFR mutant NSCLC, CNS 
penetration is limited at standard daily dosing. Concentrations 
in cerebrospinal fluid exceeding the half maximal inhibitory 
concentration for EGFR mutant lung cancer cells in patients 
with BM and leptomeningeal metastases (LM) that developed 
despite standard daily erlotinib or other EGFR TKIs were 
achieved with weekly intermittent “pulsatile” administration of 
high-dose (1,500 mg) erlotinib (24). ICRR was 67% (Table 1). 
Median time to CNS progression was 2.7  months (range, 
0.8–14.5  months), and median OS was 12  months (range, 
2.5 months–not reached) (24).
Second-Generation TKi
In both LUX-Lung 3 and LUX-Lung 6 studies, there was a 
non-significant trend toward improved PFS with afatinib versus 
chemotherapy in patients with asymptomatic BM (LUX-Lung 
3:11.1 versus 5.4 months, HR = 0.54, P = 0.1378; LUX-Lung 6:8.2 
versus 4.7  months, HR =  0.47, P =  0.1060) (25). In combined 
analysis, PFS was significantly improved with afatinib versus 
with chemotherapy in patients with BM (8.2 versus 5.4 months; 
HR = 0.50; P = 0.0297) (25).
Afatinib significantly improved the ORR versus chemotherapy 
in patients with BM. For LUX-Lung 3, ORR for afatinib was 
70.0% (95% CI, 45.7–88.1) versus chemotherapy 20.0% (95% CI, 
4.3–48.1) in patients with BM. The LUX-Lung 3 DCR for afatinib 
was 95.0% (95% CI, 75.1–99.9) versus chemotherapy 80.0% (95% 
CI, 51.9–95.7) in patients with BM. In LUX-Lung 6, ORR for 
afatinib was 75.0% (95% CI, 55.1–89.3) versus chemotherapy 
27.8% (95% CI, 9.7–53.5) in patients with BM. The LUX-Lung 6 
DCR for afatinib was 89.3% (95% CI, 71.8–97.7) versus chemo-
therapy 72.2% (95% CI, 46.5–90.3). There was no significant dif-
ference in OS in patients with BM who were treated with afatinib 
or chemotherapy.
These findings perhaps demonstrate a clinical benefit of 
afatinib in EGFR mutation–positive patients with NSCLC and 
asymptomatic BM. However, the role of afatinib in active BM 
remains to be clarified since this was an exclusion criterion in this 
study. ICRRs were not assessed in this study (Table 1). Therefore, 
no direct conclusions can be made regarding afatinib’s ability to 
cross the BBB in concentrations sufficient to elicit CNS responses.
Despite limited evidence of EGFR TKIs providing benefit in 
a few patients with EGFR mutation-positive NSCLC with BM, a 
clinical need for novel EGFR TKIs with improved efficacy against 
BM still exists.
Osimertinib in Leptomeningeal Disease
Leptomeningeal metastases are seen in 3–5% of NSCLC (42) and 
in 9% of EGFR mutation-positive patients (43). Osimertinib is an 
irreversible EGFR TKI that targets activating mutations (EGFRm) 
and resistance mutations (T790M). Osimertinib induced sus-
tained tumor regression in an EGFRm PC9 mouse BM model. 
PET imaging showed higher levels of osimetinib levels in NHP 
and mouse models, in contrast to rociletinib and gefitinib (39).
In previous trials, osimertinib demonstrated robust systemic 
activity in patients with EGFRm NSCLC and BM and has shown 
CNS penetration with sustained tumor regression in BM (44). In 
the phase 1 BLOOM study, two third-generation EGFR TKIs—
osimertinib and AZD3759—were studied in patients with EGFR 
mutation-positive advanced NSCLC (26). Neurological function 
improved from baseline in 24% (5/21) patients. Radiological 
improvements in LM were seen in 33% (7/21) patients, and 43% 
(9/21) had stable disease (SD) (Table  1). Clearance of tumor 
TABLe 2 | effect of immunotherapy on BM in non-small cell lung cancer 
trials.
Trial Treatment iDCR iCRR (%)
CheckMate 017 (47) Nivolumab 49% 19
CheckMate 012 (48) Nivolumab Not described 16.7
NCT12085070 (49) Pembrolizumab Not described 33
BM, brain metastases; IDCR, intracranial disease control rate; ICRR, intracranial 
response rate.
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cells from the CSF occurred in two patients at two consecutive 
visits. Time on treatment suggests durable clinical benefit, with 
15 patients remaining on treatment, 7 of whom have been on 
treatment for >9 months.
AZD3759 in BM
AZD3759 is a reversible inhibitor of EGFR-activating mutations 
that was designed to achieve high exposure in the plasma and 
CNS. AZD3759 has high passive permeability (29.5 × 10−6 cm/s) 
and is not a substrate of the efflux transporters Pgp or BCRP at the 
BBB. In vivo, AZD3759 reached distribution equilibrium in rats, 
mice, and monkeys (Kpuu,brain and Kpuu,CSF > 0.5), suggesting BBB 
penetration (45). AZD3759 induced significant tumor regression 
and dramatically improved animal survival in the BM model (45).
The AZD3759 cohort of the BLOOM trial evaluated the 
safety, tolerability, and early efficacy of AZD3759 in 29 patients 
with advanced EGFR mutation-positive NSCLC and metastases, 
including LM (27). Patients with non-LM BM were required to 
have at least one measurable intracranial or extracranial lesion. 
Patients with LM had a diagnosis confirmed by positive CSF 
cytology. All patients received at least one prior line of EGFR 
TKI therapy and chemotherapy. In addition, 34% of patients 
underwent prior whole-brain radiotherapy.
AZD3759 demonstrated encouraging intracranial antitumor 
activity. Among 21 patients with measurable BM, 11 patients 
demonstrated tumor shrinkage in the target brain lesion at 
AZD3759 doses of ≥50 mg BID (Table 1). In this group, there 
were three confirmed partial responses (PR) and three uncon-
firmed PRs. Among 22 patients with measurable extracranial 
lesions, 8 experienced tumor shrinkage, with 1 unconfirmed 
partial response. At the time of data cutoff, 5 of 29 patients 
remained on treatment with AZD3759. The longest duration of 
treatment was 48 weeks.
Beyond EGFR and ALK
Apart from EGFR mutation and ALK translocations other distinct 
molecular subtypes of NSCLC depend on oncogenic molecular 
aberrations (driver mutations) for their malignant phenotype. 
Limited but promising data exist for the treatment of BM on novel 
molecular targets such as ROS1, BRAF, KRAS, HER2, c-MET, 
RET, PIK3CA, FGFR1, and DDR2 (46).
iMMUnOTHeRAPY
nivolumab
Nivolumab, a human IgG4 anti-PD-1 monoclonal antibody is 
active in the second-line treatment of metastatic NSCLC after 
progression on a platinum-based chemotherapy. Experience in 
routine clinical practice may differ from that seen in a controlled 
clinical trial. In a randomized phase 3 trial (CheckMate 017), 
the effect of nivolumab was studied in patients with advanced 
squamous NSCLC and central CNS metastases in a real-world, 
expanded access program (EAP) in Italy (47). Three hundred 
seventy-one patients participated in the EAP at 96 centers in 
Italy. Thirty-seven of 371 (10%) patients had asymptomatic and 
controlled CNS metastases. The DCR was 49% among patients 
with CNS metastases, with CR in 1 patient, PR in 6 patients, SD 
in 11 patients, and PD in 19 patients (Table 2), while the ORR 
in patients with CNS metastases was 7/37 (19%) (Table 2). OS 
rate at 12 months was 35% for patients with CNS metastases and 
39% for all patients. The median OS was 5.8 months (95% CI, 
1.8–9.8) for patients with CNS metastases and 7.9 months (95% 
CI, 6.2–9.6) for all patients. The PFS rate at 12 months was 31% 
for patients with CNS metastases and 27% for all patients. The 
median PFS was 4.9 months (95% CI, 2.7–7.1) for patients with 
CNS metastases and 4.2 months (95% CI, 3.4–5.0) for all patients.
In the Goldman et al. abstract 9,038 analysis presented ASCO 
2016, pooled data from nivolumab studies [CheckMate 063 (50), 
CheckMate 017 (47), and CheckMate 057 (51)] were assessed 
to determine efficacy and safety of nivolumab in patients with 
previously treated, asymptomatic CNS metastases at baseline 
and patients with untreated, asymptomatic CNS metastases at 
baseline. The best response to most recent prior therapy dem-
onstrated in the nivolumab with CNS metastases arm was CR/
PR of 13/46 (28%), SD of 15/46 (33%), and PD of 18/46 (39%), 
compared to the docetaxel with CNS metastases arm with CR/PR 
8/42 (19%), SD 13/42 (31%), and PD 18/42 (43%) (48). Among 
patients with pretreated CNS metastases, median OS was longer 
in the nivolumab group (8.4 months; 95% CI, 4.99–11.6) com-
pared to the docetaxel group (6.2 months; 95% CI, 4.4–9.23). The 
frequency of and time to new CNS lesions were similar across 
treatment groups. Furthermore, 8/46 (17%) patients developed 
new CNS lesions in the nivolumab with CNS metastases arm 
with a median (range) of 3 (1.9–10.4) months, while 9/42 (21%) 
patients developed new CNS lesions in the docetaxel with CNS 
metastases arm with a median (range) of 2 (0.5–8.0).
Moreover, in CheckMate 012 Arm M, 2 of 12 patients 
(16.7%) with untreated CNS metastases achieved intracranial 
responses, including one intracranial CR lasting >10.5 months 
(48) (Table  2). These results support further investigation of 
nivolumab monotherapy in patients with NSCLC and asympto-
matic CNS metastases.
Pembrolizumab
Pembrolizumab, a fully human anti-PD-1 monoclonal antibody is 
approved in first- and second-line treatment of metastatic NSCLC. 
NCT02085070 is a phase 2 study of pembrolizumab in patients 
with metastatic melanoma and NSCLC with untreated or progres-
sive BM. The effect of drugs on untreated BM remains unclear 
because most clinical trials exclude these patients. Early data 
demonstrated that there was an ICRR of 6/18 (33%) in the NSCLC 
on pembrolizumab 10 mg/kg arm, similar to the systemic response 
rate (49) (Table 2). The median OS was 7.7 months to date.
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The available data for the use of anti-PD-1 agents in the treat-
ment of BM do not yet include data on PD-L1 status. These data 
when available could suggest higher response rates based on the 
level of PD-L1 positivity.
COnCLUSiOn
Current standard of care for BM that require immediate local 
intervention (based on symptoms, location, size, or other 
concerning features) is craniotomy with resection or radiation 
therapy. There is still a role in integrating locally ablative therapy 
(LAT) in combination with targeted therapy and immunotherapy 
in patients with oligometastatic BM that are limited or have low 
metastatic tumor burden (52).
Prior to the advent of second-generation therapies for BM 
developing while on crizotinib, the only alternatives were abla-
tion of oligometastatic brain lesion with LAT and continuing 
crizotinib (28). Using WBRT with concurrent erlotinib (53) 
was also a viable option rather than changing to traditional 
chemotherapy.
However, recent data showing dramatic and prolonged 
responses in BM patients treated with EGFR and ALK TKIs have 
suggested that delaying LAT and WBRT may be a valid treat-
ment option for patients with asymptomatic BM from NSCLC, 
especially for those with EGFR-activating mutations or harboring 
ALK rearrangement.
The challenge will be to determine the optimal sequence of 
agents and modalities (WBRT and SRS). Perhaps serial genotyp-
ing, the degree of BM symptoms, and the toxicity profiles will 
serve to individualize treatments and determine the role of these 
targeted therapies in the therapeutic armamentarium of BM.
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